These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
396 related articles for article (PubMed ID: 19566568)
1. The effect of the levonorgestrel releasing intrauterine system on endometrial hyperplasia: an Australian study and systematic review. Buttini MJ; Jordan SJ; Webb PM Aust N Z J Obstet Gynaecol; 2009 Jun; 49(3):316-22. PubMed ID: 19566568 [TBL] [Abstract][Full Text] [Related]
3. Management of Endometrial Hyperplasia With a Levonorgestrel-Releasing Intrauterine System: A Korean Gynecologic-Oncology Group Study. Kim MK; Seong SJ; Kim JW; Jeon S; Choi HS; Lee IH; Lee JH; Ju W; Song ES; Park H; Ryu HS; Lee C; Kang SB Int J Gynecol Cancer; 2016 May; 26(4):711-5. PubMed ID: 26905333 [TBL] [Abstract][Full Text] [Related]
4. LNG-IUS versus oral progestogen treatment for endometrial hyperplasia: a long-term comparative cohort study. Gallos ID; Krishan P; Shehmar M; Ganesan R; Gupta JK Hum Reprod; 2013 Nov; 28(11):2966-71. PubMed ID: 23975691 [TBL] [Abstract][Full Text] [Related]
5. The effectiveness of a levonorgestrel-releasing intrauterine system (LNG-IUS) in the treatment of endometrial hyperplasia--a long-term follow-up study. Varma R; Soneja H; Bhatia K; Ganesan R; Rollason T; Clark TJ; Gupta JK Eur J Obstet Gynecol Reprod Biol; 2008 Aug; 139(2):169-75. PubMed ID: 18440693 [TBL] [Abstract][Full Text] [Related]
6. Levonorgestrel-releasing intrauterine system vs oral progestins for non-atypical endometrial hyperplasia: a systematic review and metaanalysis of randomized trials. Abu Hashim H; Ghayaty E; El Rakhawy M Am J Obstet Gynecol; 2015 Oct; 213(4):469-78. PubMed ID: 25797236 [TBL] [Abstract][Full Text] [Related]
7. Oral and intrauterine progestogens for atypical endometrial hyperplasia. Luo L; Luo B; Zheng Y; Zhang H; Li J; Sidell N Cochrane Database Syst Rev; 2018 Dec; 12(12):CD009458. PubMed ID: 30521671 [TBL] [Abstract][Full Text] [Related]
8. Levonorgestrel intrauterine system for endometrial protection in women with breast cancer on adjuvant tamoxifen. Chin J; Konje JC; Hickey M Cochrane Database Syst Rev; 2009 Oct; (4):CD007245. PubMed ID: 19821400 [TBL] [Abstract][Full Text] [Related]
9. Relapse of endometrial hyperplasia after conservative treatment: a cohort study with long-term follow-up. Gallos ID; Krishan P; Shehmar M; Ganesan R; Gupta JK Hum Reprod; 2013 May; 28(5):1231-6. PubMed ID: 23466671 [TBL] [Abstract][Full Text] [Related]
10. Oral Progestogens Versus Levonorgestrel-Releasing Intrauterine System for Treatment of Endometrial Intraepithelial Neoplasia. Marnach ML; Butler KA; Henry MR; Hutz CE; Langstraat CL; Lohse CM; Casey PM J Womens Health (Larchmt); 2017 Apr; 26(4):368-373. PubMed ID: 27901412 [TBL] [Abstract][Full Text] [Related]
11. Levonorgestrel-releasing intrauterine device versus dydrogesterone for management of endometrial hyperplasia without atypia. El Behery MM; Saleh HS; Ibrahiem MA; Kamal EM; Kassem GA; Mohamed Mel S Reprod Sci; 2015 Mar; 22(3):329-34. PubMed ID: 25001020 [TBL] [Abstract][Full Text] [Related]
12. Levonorgestrel intrauterine system for endometrial protection in women with breast cancer on adjuvant tamoxifen. Dominick S; Hickey M; Chin J; Su HI Cochrane Database Syst Rev; 2015 Dec; 2015(12):CD007245. PubMed ID: 26649916 [TBL] [Abstract][Full Text] [Related]
13. Comparative effects of different treatments based on the levonorgestrel intrauterine system in endometrial carcinoma and endometrial hyperplasia patients: a network meta-analysis. Tao M; Wu T; Zhou X; Du X; Ling K; Liang Z Arch Gynecol Obstet; 2024 Sep; 310(3):1315-1329. PubMed ID: 38980346 [TBL] [Abstract][Full Text] [Related]
14. Levonorgestrel intrauterine system for endometrial protection in women with breast cancer on adjuvant tamoxifen. Romero SA; Young K; Hickey M; Su HI Cochrane Database Syst Rev; 2020 Dec; 12(12):CD007245. PubMed ID: 33348436 [TBL] [Abstract][Full Text] [Related]
15. Efficacy of the Levonorgestrel-Releasing Intrauterine System on IVF-ET Outcomes in PCOS With Simple Endometrial Hyperplasia. Bian J; Shao H; Liu H; Li H; Fang L; Xing C; Wang L; Tao M Reprod Sci; 2015 Jun; 22(6):758-66. PubMed ID: 25536958 [TBL] [Abstract][Full Text] [Related]
16. Efficacy of levonorgestrel-releasing intrauterine system versus oral progestins in treatment of simple endometrial hyperplasia without atypia. Ismail MT; Fahmy DM; Elshmaa NS Reprod Sci; 2013 Jan; 20(1):45-50. PubMed ID: 23203322 [TBL] [Abstract][Full Text] [Related]
17. Levonorgestrel-releasing intrauterine system versus oral medroxyprogesterone acetate in infertile women with endometrial hyperplasia without atypia. Campo G; Rebecchi A; Vanni VS; Pagliardini L; Patruno C; Papaleo E; Candiani M; Giardina P Reprod Biomed Online; 2021 Nov; 43(5):864-870. PubMed ID: 34629315 [TBL] [Abstract][Full Text] [Related]
18. Use of levonorgestrel-releasing intrauterine system in the prevention and treatment of endometrial hyperplasia. Ewies AA; Alfhaily F Obstet Gynecol Surv; 2012 Nov; 67(11):726-33. PubMed ID: 23151756 [TBL] [Abstract][Full Text] [Related]
19. Low-dose LNG-IUS as Therapy for Endometrial Hyperplasia. A Prospective Cohort Pilot Study. Sletten ET; Arnes M; Vereide AB; Ørbo A Anticancer Res; 2018 May; 38(5):2883-2889. PubMed ID: 29715112 [TBL] [Abstract][Full Text] [Related]
20. The efficacy of levonorgestrel intrauterine systems for endometrial protection: a systematic review. Wan YL; Holland C Climacteric; 2011 Dec; 14(6):622-32. PubMed ID: 22017273 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]